Skip to main content

Table 4 Comparison of the current study with data on COPD cohorts from the literature

From: Case-finding for alpha1-antitrypsin deficiency in Kazakh patients with COPD

Phenotype Studies
(n = number of patients)
Normal phenotype Alpha-1-antitrypsin mutation Phenotypes Inclusion criteria
PiMM n % PiMZ n % PiMS n % PiSS n % PiSZ n % PiZZ n % Other phenotypes n %
Mittman et al. 1974 [43]
(n = 240)
USA
194
80,8%
20
8,4%
17
7,1%
1
0,4%
2
0,8%
6
2,5%
0
0%
Chronic bronchitis and/or emphysema
Cox et al. 1976 [44]
(n = 163)
USA
139
85,3%
8
4,9%
7
4,3%
0
0%
0
0%
8
4,9%
1
0,6%
COPD and aged over 18 years
Liebermann et al. 1986 [45]
(n = 965)
USA
not indicated 74
7,7%
86
8,9%
3
0,3%
3
0,3%
18
1,9%
not indicated COPD
Sitkauskiene et al. 2008 [46] (n = 1167)
Lithuania
not indicated 40
3,4%
39
3,3%
1
0,1%
3
0,3%
8
0,7%
0
0%
COPD according to GOLD
Sabri Denden et al. 2008 [47]
(n = 120)
Tunisia
114
95%
1
0.83%
0
0%
0
0%
0
0%
0
0%
5
4,2%
COPD according to GOLD
Molina et al. [36] 2009
(n = 596)
Spain
487
81,7%
16
2,7%
80
13,4%
10
1,7%
1
0,2%
2
0,3%
0
0%
COPD according to GOLD
Novak T et al. 2011, [48] (n = 105)
Germany
94
89,5%
4
3,8%
6
5,7%
0
0%
0
0%
1
1,0%
0
0%
COPD according to GOLD
Sydykova S. et al. 2008 [49]
Kirgizstan
(n = 125)
139
97,2%
3
2,1%
0
0%
0
0%
0
0%
1
0,7%
0
0%
COPD according to GOLD
Rahaghi et al. 2012 [50] (n = 3152)
USA
2780
88,2%
124
3,9%
225
7,1%
9
0,28%
10
0,32%
10
0,32%
0
0%
Case-finding in GOLD II-IV sent for Spirometry excluded previously tested patients
This study
(n = 187)
Kazakhstan
181
96.8
3
1,6%
1
0,5%
0
0%
0
0%
0
0%
2
1,1%
COPD according to GOLD